Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole

Current Medical Research and Opinion

Volumn 29, Issue 10, 2013, Pages 1241-1251

  Potkin, Steven G ^a   Raoufinia, Arash ^b   Mallikaarjun, Suresh ^b   Bricmont, Patricia ^b   Peters Strickland, Timothy ^b   Kasper, William ^b   Baker, Ross A ^b   Eramo, Anna ^c   Sanchez, Raymond ^b   McQuade, Robert ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^c LUNDBECK RESEARCH USA   (United States)

Author keywords

Aripiprazole once monthly; Atypical antipsychotics; Long acting injectable; Schizophrenia; Switching

Indexed keywords

ARIPIPRAZOLE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AKATHISIA; ARTICLE; CONCENTRATION (PARAMETERS); CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DSM-IV-TR; DYSTONIA; FATIGUE; FEMALE; FOLLOW UP; HUMAN; INJECTION SITE PAIN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MUSCLE SPASM; RECOMMENDED DRUG DOSE; RESTLESSNESS; RISK ASSESSMENT; SCHIZOPHRENIA; SIDE EFFECT; SINGLE DRUG DOSE; TOOTH ABSCESS; TOOTH PAIN; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; QUINOLONES; RISK FACTORS; SCHIZOPHRENIA; SEX FACTORS; TIME FACTORS;

EID: 84884489165     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2013.821973     Document Type: Article

References (37)

1. Falkai P, Wobrock T, Lieberman J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psychiatry 2006;7:5-40 (Pubitemid 43878525)
2. Byerly MJ, Nakonezny PA, Lescouflair E. Antipsychotic medication adherence in schizophrenia. Psychiatr Clin North Am 2007;30:437-52 (Pubitemid 47284561)
3. Valenstein M, Ganoczy D, McCarthy JF, et al. Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. J Clin Psychiatry 2006;67:1542-50 (Pubitemid 44787436)
4. Llorca PM. Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res 2008;161:235-47
5. Sun SX, Liu GG, Christensen DB, et al. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. Curr Med Res Opin 2007;23:2305-12 (Pubitemid 350033432)
6. Marcus S, Olfson M. Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophr Bull 2008;34:173-80 (Pubitemid 350262282)
7. Gilmer TP, Dolder CR, Lacro JP, et al. Adherence to treatment with antipsych-otic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161:692-9 (Pubitemid 38445514)
8. Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehos-pitalization among California Medicaid patients with schizophrenia. Psychiatric Services 2004;55:886-91 (Pubitemid 39025215)
9. Ascher-Svanum H, Zhu B, Faries DE, et al. Medication adherence levels and differential use of mental-health services in the treatment of schizophrenia. BMC Research Notes 2009;2:6
10. Samtani MN, Gopal S, Gassmann-Mayer C, et al. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data. CNS Drugs 2011;25:829-45
11. Kane J, Sanchez R, Perry P, et al. Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2012;73:617-24
12. Leucht C, Heres S, Kane JM, et al. Oral versus depot antipsychotic drugs for schizophrenia-a critical systematic review and meta-analysis of randomised long-term trials. Schizophrenia Res 2011;127:83-92
13. Edwards NC, Locklear JC, Rupnow MF, et al. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. PharmacoEconomics 2005;23(Suppl 1):75-89
14. Olivares JM, Rodriguez-Martinez A, Buron JA, et al. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risper-idone in patients with schizophrenia: a 12-and 24-month follow-up from the e-STAR database in Spain. Appl Health Econom Health Pol 2008;6:41-53
15. Haycox A. Pharmacoeconomics of long-acting risperidone: results and validity of cost-effectiveness models. PharmacoEconomics 2005;23(Suppl 1):3-16
16. Zhornitsky S, Stip E. Oral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence: a systematic review. Schizophr Res Treat 2012;2012:407171
17. Kishimoto T, Robenzadeh A, Leucht C, et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull 2013 Jan 2. [Epub ahead of print]
18. Kirson NY, Weiden PJ, Yermakov S, et al. Efficacy and effectiveness of depot vs. oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psych 2013;74:568-75
19. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302:381-9 (Pubitemid 34680462)
20. Janssen Pharmaceuticals Inc. Risperidone long-acting injectable prescribing information. 2011. Available at: http://www.invegasustenna.com/ important-product-information [Last accessed August 2012]
21. Janssen Pharmaceuticals Inc. Paliperidone palmitate injectable prescribing information. 2012. Available at: http: http://www.invegasustenna. com/impor-tant-product-information [Last accessed August 2012]
22. Mallikaarjun S, Kane JM, McQuade R, et al. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res 2013;Submitted
23. Lindenmayer JP, Eerdekens E, Berry SA, et al. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 2004;65:1084-9
24. Rosa F, Schreiner A, Thomas P, et al. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable. Clin Drug Investig 2012;32:267-79
25. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-6 (Pubitemid 19154942)
26. Guy W. Abnormal Involuntary Movement Scale (AIMS). US Department of Health Education and Welfare ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: National Institute of Mental Health, 1976:534-7
27. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19
28. Chappell P, Feltner DE, Makumi C, et al. Initial validity and reliability data on the Columbia-Suicide Severity Rating Scale. Am J Psychiatry 2012;169:662-3; author reply 63
29. Kay S, Fiszbein A, Opler L. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76 (Pubitemid 18039085)
30. Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised. Rockville, MD: US Department of Health Services, 1976
31. Fleischhacker WW, Sanchez R, Johnson B, et al. Long-term safety and tol-erability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. Int Clin Psychopharmacol 2013;28:171-6
32. Fleischhacker WW, Sanchez R, Perry P, et al. Aripiprazole once-monthly for the treatment of schizophrenia: a double-blind, randomized, non-inferiority study vs. oral aripiprazole. Neuropsychopharmacology 2012;28:S339
33. Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 2004;44:179-87 (Pubitemid 38114317)
34. ADA/APA/AACE/NAASO. Consensus development conference on antipsych-otic drugs and obesity and diabetes. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Diabetes Care 2004;27:596-601
35. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007;68(Suppl 1):20-7
36. De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 2012;8:114-26
37. Stroup TS, McEvoy JP, Ring KD, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 2011;168:947-56